B. Riley Securities analyst Mayank Mamtani maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $270 to $200.
B. Riley Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $200
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.